Xencor Inc.

4 trials 2 recruiting Commercial sponsor

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

2 Recruiting

1 Completed trials

14 Countries active

5 Unique IMPs

100% Results reported

Phase II

Phase I/II

Phase I

Phase II: 1 Phase I/II: 1 Phase I: 2

Oversight events:

5 temporary halts across 1 trial

View oversight register →

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Clear cell renal cell carcinoma 1 Non-small cell lung cancer 1

Top IMPs

CARBOPLATIN 1 PEMBROLIZUMAB 1 PEMETREXED 1 VUDALIMAB 1 XMAB942 1

All trials

4 total

A Study Testing the Investigational Drug XmAb541 in people with Advanced Cancer Pending

2025-521981-90-00 Phase I 4 countries
A Multi-Stage Study to Test a New Drug in Healthy Adult Volunteers, Then in Adults with Ulcerative Colitis Recruiting

2025-522702-21-00 Phase II 11 countries XMAB942
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma Recruiting

2024-513619-28-00 Phase I 3 countries
A study to compare effectiveness and safety of a combination of vudalimab or pembrolizumab with chemotherapy in participants with advanced l… Ended

2023-509644-10-00 Phase I/II 7 countries CARBOPLATIN; PEMBROLIZUMAB; PEMETREXED; VUDALIMAB

Showing 1–4 of 4 trials

← All sponsors A–Z